A Phase Ib/II study of ilixadencel in combination with checkpoint inhibitors (CPIs) for head & neck cancer, gastric adenocarcinoma and non-small cell lung cancer

Trial Profile

A Phase Ib/II study of ilixadencel in combination with checkpoint inhibitors (CPIs) for head & neck cancer, gastric adenocarcinoma and non-small cell lung cancer

Planning
Phase of Trial: Phase I/II

Latest Information Update: 23 Jul 2018

At a glance

  • Drugs Ilixadencel (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Head and neck cancer; Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ILIAD
  • Sponsors Immunicum
  • Most Recent Events

    • 23 Jul 2018 According to an Immunicum media release, the US FDA has approved the clinical trial protocol for this Phase Ib/II trial. The trial protocol has been developed with guidance from EU regulatory authorities as well as from the FDA.
    • 09 Apr 2018 New trial record
    • 03 Apr 2018 According to an Immunicum media release, the Company plans to enroll the first patient during the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top